GLUE Earnings Date: Nov 5, 2026 (Estimated) — Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is GLUE's next earnings date?
Monte Rosa Therapeutics, Inc. (GLUE) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.24 on revenue of $33.9M.
How did GLUE do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Monte Rosa Therapeutics, Inc. posted EPS of -$0.43 versus the -$0.38 estimate, a miss of 26.5%. Revenue was $9.0M against a $12.9M estimate. The stock's 1-day post-earnings move was +0.6%.
How much does GLUE stock move after earnings?
GLUE beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.38 | -0.43 | -26.47% | $9.0M | ❌ Miss | +0.64% | +2.18% | -7.88% |
| 2026-05-07 | Q1 2026 | -0.36 | -0.45 | -25.00% | $4.2M | ❌ Miss | -2.84% | -7.01% | -19.72% |
| 2026-03-17 | Q4 2025 | -0.39 | -0.55 | -41.03% | $2.8M | ❌ Miss | -1.96% | -8.07% | +11.50% |
| 2025-11-06 | Q3 2025 | -0.37 | -0.33 | +10.81% | $12.8M | ✅ Beat | +5.69% | +15.03% | +41.43% |
| 2025-08-07 | Q2 2025 | -0.34 | -0.15 | +55.88% | $23.2M | ✅ Beat | -2.87% | +1.95% | +13.43% |
| 2025-05-08 | Q1 2025 | -0.32 | 0.57 | +278.12% | $84.9M | ✅ Beat | +9.61% | -3.90% | +30.13% |
| 2025-03-20 | Q4 2024 | -0.37 | 0.23 | +162.16% | $60.6M | ✅ Beat | +5.37% | -18.06% | -32.09% |
| 2024-11-07 | Q3 2024 | -0.49 | -0.29 | +40.82% | $9.2M | ✅ Beat | +0.85% | -8.68% | -0.42% |
Showing last 8 quarters.